VectorY Therapeutics

#Amyotrophic lateral sclerosis (ALS) #Neuroscience #Phase I trial #Therapeutic Antibodies #VectorY Therapeutics

Vectorised antibody takes ‘innovative approach’ to ALS treatment

VectorY Therapeutics has announced that the first participant has been dosed in its Phase I/II PIONEER-ALS clinical trial of VTx-002 in people with amyotrophic lateral sclerosis (ALS).  VTx-002 is a first-in-class vectorised antibody designed to holistically target TDP-43 pathology in ALS recently granted FDA Fast… Read More

#News